Addendum: ENTA’s Mavyret/Glecaprevir royalties from ABBV will be in the 17% tier for almost all of the Jul-Sep 2018 sales and for all of the Oct-Dec 2018 sales.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.